CBIS - Cannabis Science Breaks Ground on Medical Dispensary TV Ads - DrStockPick.com Stock Alert!
________
Breaking News! 9/9/2010 12:52pm EST
RockBrook Gears Up to Commercialize the Cannabis Science Brand of Pharmaceutical Products as Another Medical Cannabis Dispensary Breaks More Industry Ground as It Airs One of the First Paid TV Ads on FOX Affiliate KTXL in Sacramento, California
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased with its progress with RockBrook Inc. as its first commercialization license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado.
The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.
On August 30, 2010, FOX affiliate KTXL (”FOX40?) aired one of the first paid U.S. television ads for a Cannabis Dispensary called CannaCare on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials.
Similarly, Cannabis Science is acquiring public testimonials using data acquired from RockBrook patients who use Cannabis Science Brands to evaluate our medical marijuana products prior to FDA clinical trials.
“It is a matter of record within the medical community that medical marijuana can have positive results in helping relieve nausea and vomiting among cancer patients receiving chemotherapy and increasing appetites among AIDS patients,” Mike Armstrong, acting general manager of KTXL in Sacramento, said in a statement e-mailed to FOX40.com, alluding that the ad is no different from that of any medicine advertised by pharmaceutical companies on local television channels and cable networks for decades.
Cannabis Science President and CEO Dr. Robert Melamede, PhD., noted, “The FOX40 ad sets a new milestone for general public acceptance of medical cannabis. Centuries of knowledge record that cannabis is an efficacious medicinal treatment for a host of ailments, yet governments continues to cling to clouded ideologies against this natural medicine and instead support man-made pharmaceuticals that often produce more harm than medicinal good.
We are optimistic that the unique holistic value of medical cannabis, with its ability to supplement our natural endocannabinoid system will continue to spread throughout the country and the world. Dispensaries currently lead the way throughout California and other U.S. states, such as Colorado where our licensed dispensary is located. The Company sees this as an opportune time to expand the marketing of its products and licensing dispensaries. We look forward to future TV marketing campaigns for Cannabis Science products and our licensed RockBrook dispensary.”
Richard Cowan, Cannabis Science CFO, added, “We are encouraged that mainstream media is accepting medical cannabis dispensary advertisements in California, which is opening the door for us to expand the advertisement of our own licensed dispensary and products. On August 30, 2010, FOX affiliate KTXL (”FOX40?) aired the first ever-paid U.S. television ad for a medical cannabis dispensary on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials. From a marketing perspective, this is a huge leap forward in giving medical cannabis dispensaries the opportunities that chemically manufactured medicines have long held.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. Cannabis Science works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, Cannabis Science is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
http://www.cannabisscience.com
________
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars from a third party (VNC Associates LLC) for one (1) day of advertising for CANNABIS SCIENCE INC (OTC BB: CBIS.OB).
Tags: Cannabis Science, CBIS, CBIS.OB, OTC:CBIS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
